Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

4SC 205

Drug Profile

4SC 205

Alternative Names: 4SC-205; LH-031

Latest Information Update: 03 Oct 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Nycomed
  • Developer 4SC; Link Health Group
  • Class Antineoplastics; Small molecules
  • Mechanism of Action KIF11 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Lymphoma; Solid tumours
  • Preclinical Liver cancer; Lung cancer

Most Recent Events

  • 03 Oct 2023 4SC 205 is still in preclinical trials for Liver cancer and Lung cancer in China (PO) (4SC pipeline, October 2023)
  • 03 Oct 2023 4SC 205 is still in phase I trials for Solid tumours and Lymphoma in China (PO) (4SC pipeline, October 2023)
  • 13 Aug 2019 Phase-I clinical trials in Lymphoma (Late- stage disease) in China, Hong Kong, Macau and Taiwan (PO)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top